Of the integrins that can potentially activate TGFβ1, only αvβ3-specific antibodies and peptides have been used in humans as part of anti-cancer therapies (Posey et al. 2001; Hersey et al. 2010; Khasraw et al. 2016) but none has achieved significant clinical success. This evidence concerns the gene TGFB1 and cancer.